Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intercept Pharmaceuticals Inc    ICPT

INTERCEPT PHARMACEUTICALS INC

(ICPT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

INTERCEPT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 05:03pm EDT

Item 5.07. Submission of Matters to a Vote of Security Holders.

Intercept Pharmaceuticals, Inc. (the "Company") held its 2019 Annual Meeting of Stockholders (the "Annual Meeting") on June 20, 2019.

At the Annual Meeting, the Company's stockholders:

1. Elected, by separate resolutions, each of the ten nominees nominated to serve

    on the Board of Directors until the 2020 Annual Meeting of Stockholders or
    until their respective successors are duly elected and qualified.



2. Approved, on a non-binding, advisory basis, the compensation of the Company's

    named executive officers as disclosed in the Company's Definitive Proxy
    Statement on Schedule 14A filed with the Securities and Exchange Commission on
    April 30, 2019 (the "Proxy Statement").



3. Ratified the appointment of KPMG LLP as the independent registered public

    accounting firm of the Company for the year ending December 31, 2019.



The final voting results on each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are as follows:




                                                                             Broker
Proposal                                              For       Withheld    Non-Votes
1. The election, by separate resolutions, of
each of the following ten nominees to serve on
the Board of Directors until the 2020 Annual
Meeting of Stockholders or until their
respective successors are duly elected and
qualified:
a) Paolo Fundarò (Proposal No. 1A)                 19,323,365   1,112,306   4,656,113

b) Mark Pruzanski, M.D. (Proposal No. 1B) 19,348,881 1,086,790 4,656,113 c) Srinivas Akkaraju, M.D., Ph.D. (Proposal No. 1C)

                                                18,522,612   1,913,059   4,656,113
d) Luca Benatti, Ph.D. (Proposal No. 1D)           20,282,199     153,472   4,656,113
e) Daniel Bradbury (Proposal No. 1E)               17,422,266   3,013,405   4,656,113

f) Keith Gottesdiener, M.D. (Proposal No. 1F) 20,340,638 95,033 4,656,113 g) Nancy Miller-Rich (Proposal No. 1G)

             20,342,860      92,811   4,656,113
h) Gino Santini (Proposal No. 1H)                  15,479,587   4,956,084   4,656,113
i) Glenn Sblendorio (Proposal No. 1I)              16,269,597   4,166,074   4,656,113
j) Daniel Welch (Proposal No. 1J)                  20,250,038     185,633   4,656,113




                                                                               Broker
Proposal                                    For       Against      Abstain    Non-Votes
2. The approval, on a non-binding,
advisory basis, of the compensation of
the Company's named executive officers
as disclosed in the Proxy Statement      20,048,861     364,116      22,694   4,656,113
3. The ratification of the appointment
of KPMG LLP as the independent
registered public accounting firm of
the Company for the year ending
December 31, 2019                        24,881,456     172,724      37,604           -

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTERCEPT PHARMACEUTICALS
06/25INTERCEPT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Ho..
AQ
05/30Intercept to Present at Upcoming Investor Conferences in June
GL
05/14INTERCEPT PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Cr..
AQ
05/10INTERCEPT PHARMACEUTICALS : to Present at Upcoming Investor Conferences in May
AQ
05/10INTERCEPT PHARMACEUTICALS : Announces Pricing of Offerings of Common Stock and C..
AQ
05/08Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Com..
GL
05/08INTERCEPT PHARMACEUTICALS : Management's Discussion and Analysis of Financial Co..
AQ
05/08INTERCEPT : 1Q Earnings Snapshot
AQ
05/08INTERCEPT PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
05/08INTERCEPT PHARMACEUTICALS : Reports First Quarter 2019 Financial Results and Pro..
AQ
More news
Financials (USD)
Sales 2019 242 M
EBIT 2019 -295 M
Net income 2019 -331 M
Finance 2019 45,1 M
Yield 2019 -
P/E ratio 2019 -6,46x
P/E ratio 2020 -7,01x
EV / Sales2019 9,09x
EV / Sales2020 6,98x
Capitalization 2 242 M
Chart INTERCEPT PHARMACEUTICALS INC
Duration : Period :
Intercept Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTERCEPT PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 156,38  $
Last Close Price 68,64  $
Spread / Highest target 254%
Spread / Average Target 128%
Spread / Lowest Target 1,98%
EPS Revisions
Managers
NameTitle
Mark E. Pruzanski President, Chief Executive Officer & Director
Paolo Fundarò Chairman
Jerome B. Durso Chief Operating Officer
Sandip S. Kapadia CFO, Treasurer & Principal Accounting Officer
David A. Shapiro Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
INTERCEPT PHARMACEUTICALS INC-31.90%2 242
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS7.47%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.94%11 908
SAREPTA THERAPEUTICS INC36.77%11 068